EPB41L3（蛋白质4.1B/Dal-1）作为晚期前列腺癌治疗靶点的潜在作用。
Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer.
作者信息
Bernkopf Dominic B, Williams Elizabeth D
机构信息
Monash University, Centre for Cancer Research, Monash Institute of Medical Research, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria, 3168, Australia.
出版信息
Expert Opin Ther Targets. 2008 Jul;12(7):845-53. doi: 10.1517/14728222.12.7.845.
BACKGROUND
Loss of erythrocyte membrane protein band 4.1-like 3 (EPB41L3; aliases: protein 4.1B, differentially expressed in adenocarcinoma of the lung-1 (Dal-1)) expression has been implicated in tumor progression.
OBJECTIVE
To evaluate literature describing the role of EPB41L3 in tumorigenesis and metastasis, and to consider whether targeting this gene would be useful in the treatment of prostate cancer.
METHODS
A literature review of studies describing EPB41L3 and its aliases was conducted. Online databases (NCBI, SwissProt) were also interrogated to collect further data.
RESULTS/CONCLUSION: A growing body of evidence supports a role for loss of EPB41L3 in tumor progression, including in prostate cancer. Therapeutic strategies that could be harnessed to upregulate EPB41L3 gene expression in prostate cancer cells are currently being developed.
背景
红细胞膜蛋白带4.1样3（EPB41L3；别名：蛋白4.1B，在肺腺癌中差异表达-1（Dal-1））表达缺失与肿瘤进展有关。
目的
评估描述EPB41L3在肿瘤发生和转移中作用的文献，并考虑靶向该基因是否对前列腺癌治疗有用。
方法
对描述EPB41L3及其别名的研究进行文献综述。还查询了在线数据库（NCBI、SwissProt）以收集更多数据。
结果/结论：越来越多的证据支持EPB41L3缺失在肿瘤进展中发挥作用，包括在前列腺癌中。目前正在开发可用于上调前列腺癌细胞中EPB41L3基因表达的治疗策略。
Zotero 插件